Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19386710 | 0.82 | NOS1 (0.45) | NOS1SLC6A3SMYD3TRPM5RAB9A | |
| SCHEMBL17828356 | 0.82 | NOS1 (0.43) | NOS1SLC6A3TRPM5RAB9A | |
| SCHEMBL6702093 | 0.76 | SLC6A3 (0.33) | NOS1SLC6A3SMYD3RAB9ALOXL2 | |
| SCHEMBL1366842 | 0.76 | — | — | |
| SCHEMBL24027177 | 0.76 | NOS1 (0.38) | NOS1SLC6A3TRPM5RAB9A | |
| SCHEMBL24297619 | 0.74 | NOS1 (0.36) | NOS1SLC6A3TRPM5RAB9A | |
| SCHEMBL6232900 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL6236907 | 0.71 | NOS1 (0.45) | NOS1SLC6A3SMYD3TRPM5LOXL2 | |
| SCHEMBL13142433 | 0.71 | NOS1 (0.48) | NOS1SLC6A3SMYD3TRPM5RAB9A | |
| SCHEMBL14298745 | 0.69 | NOS1 (0.35) | NOS1SLC6A3TRPM5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | NOS1 3801/4885SLC6A3 109/4885SMYD3 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.